NMN and mobility in older men: a trial with an important error

The promising result needs its main limitation

A small NMN trial in healthy older men found exploratory signals in gait speed and left-hand grip, while the primary muscle-mass analyses were negative. Its major complication was a supplier error affecting treatment assignment after the six-week visit. ^[1] A summary that mentions only improved mobility gives an incomplete impression. The study remains worth reading precisely because it shows both biological activity and the practical weaknesses that can limit an early result. It cannot establish that any retail NMN product prevents disability or that an older person with declining function should treat themselves.

Forty-two men entered the experiment

Igarashi and colleagues randomized forty-two men aged at least sixty-five, twenty-one per group, to 250 mg oral NMN daily or placebo for twelve weeks. ^[1] These were healthy volunteers selected for a research protocol, not a broad clinic population with weakness or falls. The actual population matters because a person seeking treatment for a diagnosed muscle disorder may differ substantially. The study amount also describes an experiment, not an individualized recommendation. A reader should not choose a capsule solely because its label reproduces that number and then assume the study’s other conditions no longer matter.

A supply error changed the analysis

At the six-week supply visit, eleven participants in each group received the other supplement. The investigators therefore excluded those twenty-two participants’ twelve-week data, leaving ten per group for the later assessment. ^[1] This is not ordinary dropout from loss of interest. It is a treatment-supply problem that materially changed the available comparison. The six-week and twelve-week results should not be presented as if the original forty-two completed the same assigned regimen throughout. The disclosure strengthens transparency, but it does not restore the information lost or remove the extra uncertainty around a small later sample.

For the broader context, read NAD+ precursors and exercise outcomes.

Some function measures moved, muscle mass did not

The report describes nominally significant gait-speed and left-grip findings, with no significant increase in skeletal muscle mass. It also reports higher whole-blood NAD-related metabolites. ^[1] The important interpretation is endpoint-specific: blood chemistry, muscle quantity and physical performance gave different answers. An exploratory result in one hand is not the same as a replicated improvement in overall strength. Nor does a null muscle-mass finding prove that no functional change is possible. The reader should preserve both observations and resist a headline that turns a limited pattern of findings into comprehensive muscle rejuvenation.

A separate older-adult trial asked another question

Kim and colleagues conducted a separate twelve-week trial in 108 older Japanese adults divided into morning or afternoon NMN and matching placebo groups, using 250 mg daily. ^[2] Its focus included sleep, fatigue and physical performance. Time effects and changes in placebo groups make it important to read between-group findings rather than celebrate improvement from baseline alone. This is not a repair of the first study’s supply error. The trials ask related questions with different designs, and their findings should be compared on those terms rather than counted as interchangeable confirmations of a broad benefit.

Newer high-dose research is a different experiment

A newer paper published in September 2026 describes a twenty-four-week randomized trial of 1,250 mg NMN daily in adults aged at least sixty-five. ^[3] That is a different amount and follow-up period from the 2022 experiment. Its existence does not retroactively validate the earlier analysis or establish that a larger retail dose is the correct choice. The useful habit is to identify the actual study being invoked rather than merge several protocols into a single ideal regimen. This focused discussion of the earlier mobility result should not be mistaken for a pooled conclusion about every later NMN trial.

Short-term tolerability is not universal suitability

The 2022 older-men study reported no serious adverse event and no significant adverse laboratory pattern under its protocol. ^[1] That is reassuring within a limited sample and duration. It does not answer every question about prolonged use, a different formulation or a person with several medical conditions. A mobility concern also deserves an appropriate clinical assessment rather than a presumption that it reflects a low NAD level. The risk of a misleading sales summary is not only an unnecessary purchase; it can also narrow attention before the actual reason for declining function has been evaluated.

What a mobility claim should demonstrate

A convincing mobility claim would identify the population, specify the practical outcome and show a worthwhile difference against an appropriate control. It should also preserve how missing or excluded data were handled. For a consumer, the question is whether the result changes confidence about walking, getting up, strength or independence, not merely whether a pathway responds. The error in the 2022 study is therefore central rather than a technical footnote. ^[1] A product page using the trial should make that limitation visible instead of selecting the most flattering measurement and omitting the circumstances that weakened it.

Keep the distinction clear with NAD+ product safety and tolerability.

How this should change a buying decision

I would read this study as an early signal requiring confirmation, not a purchasing mandate. It shows why NMN research deserves careful attention while illustrating how much can disappear from a simplified supplement claim. If a clinician is evaluating declining mobility, bring the actual concern and relevant history, not a self-assigned NAD diagnosis. For product comparisons, separate formula clarity, cost and convenience from the strength of clinical evidence. A well-described product can be easier to assess without becoming a demonstrated treatment for age-related weakness, and a matching milligram label cannot make an exploratory trial more definitive.

For a separate practical comparison, see DoNotAge Pure NMN review; a product review does not turn this study into a treatment recommendation.